Transbiohope | Impact
Transbio project, oriented to the development of an in vitro diagnostic kit for the treatment of chronic rejection with immunosuppressants. H2020 program of the European Union
"trasplante riñón” “diagnóstico in vitro” “in vitro diagnosis” “trasplante renal” “H2020” “European Commission project” “renal transplant” “kidney transplant” “start-up” “Tres Cantos” “biomedicina” “biomedicine” “biotechnology” “immunobiogram” “inmunobiograma” “tratamiento inmunosupresores” “Treatment with immunosuppressants”
15691
page-template,page-template-full_width,page-template-full_width-php,page,page-id-15691,page-child,parent-pageid-15655,ajax_fade,page_not_loaded,,qode-title-hidden,qode-theme-ver-10.1.1,wpb-js-composer js-comp-ver-5.0.1,vc_responsive

IMPACT

About 3.28 million people living with a transplanted kidney; potential BIOHOPE impact seems unquestionable
About 5 million people living with a transplanted kidney worldwide. The renal transplant diagnosis market will reach a global size of €645M in 2019, with a Compound Annual Growth Rate (CAGR) of 6,5%

The number of patients in need of a kidney replacement is exponentially growing due to several factors, such as longevity, obesity, diabetes, smoking and drinking habits. Considering that worldwide, the number of people receiving renal transplantation annually (incidence) is estimated at about 80,000 people, growing by approximately 6% annually and representing a prevalence of about 450 patients per million population (p.m.p), or what is the same, about 3.28 million people living with a transplanted kidney; potential BIOHOPE impact seems unquestionable.

In terms of impact over health outcomes and societal benefits, BIOHOPE will offer an integral solution to overcome the main current challenges in renal transplantation, as it will unleash the following novelties in patient care:

  • Reducing chronic rejection by the early identification of patients at risk of immunologic response. Early diagnosis of chronic rejection will open the possibility for clinicians to make the necessary adjustments in immunosuppressive therapy, as a way to avoid organ rejection to actually take place.
  • Reducing or even eliminating the side effects of immunosuppressant drugs in patients showing operational tolerance to the transplanted organ, by enabling reduction or even withdrawal of the immunosuppressive medication.
  • Reducing the side effects of immunosuppressant drugs by enabling the determination of the most effective immunosuppression regime for each patient individually and monitoring of treatment efficiency along time, thus opening the door to treatment personalization.

These solutions have been defined by Transplantation Nephrologists as “historical advances” in case Biohope´s products are positively validated in the clinic, therefore our major impact is clearly an important improvement in Transplantation care in Europe.

In terms of business, there is also an important potential for Biohope to grow in the Biomedicine sector as a leading company.

Activity in kidney transplantation

  • Europe

  • USA

  • LatAm

  • Rest of the world

Geographically, North America and Europe command the largest share of the global transplant diagnostics. The transplant diagnostics market in the North America & Europe is primarily driven by factors such as increase in public and private funding and growing number of solid organ transplantation procedures. In terms of segmentation based on the application, renal transplantation leads the market (67% share, see figure 1) with an annual renal replacement therapy (RRT) incidence (new transplants performed each year) of almost 80,000 growing by approximately 6% annually and an ESKD have an average global prevalence of 450 p.m.p., meaning about 3.28 million people living with a transplanted kidney worldwide. The regions reporting a higher activity in kidney transplantation were Europe (19,670 transplants performed in 2014, a 25% of the total) followed by the USA (17,815 transplant in 2014, a 22% of the total). Latin America (LATAM with 11,770 transplants reported in 2014 (a 15% of the total). The renal transplant diagnosis market will reach a global size of €645M in 2019, with a Compound Annual Growth Rate (CAGR) of 6,5%.

For public administration and private health care systems, Biohope will save a lot of expenses considering the huge costs associated with second transplants and very expensive life-length dialysis. We have calculated and for every kidney transplanted survives, the total savings for public administration per patient/year in Europe ascend at least to 40.000€. Taking in account that there 25.383 transplants in Europe per year, there is a worthy of consideration saving.